Search the Epitope Variant and Escape Mutation Database

Help

Found 5 matching records:

Displaying record number 55002

HXB2 Location Gag(147-155) Gag Epitope Map
View variants at this location

ISPRTLNAW

`raPRTLNAW`		non-susceptible form
`mSPRTLNAW`		non-susceptible form; susceptible form
`vSPRTLNAW`		non-susceptible form; susceptible form
`ltPRTLNAW`		non-susceptible form; susceptible form
`vtPRTLNAW`		non-susceptible form; susceptible form
`ISaRTLNAW`		non-susceptible form; susceptible form
`IaPRTLNAr`		non-susceptible form
`lSPRTLNAW`		diminished response; susceptible form

Epitope Name ISP

Species (MHC/HLA) human(B*57:01)

Variant Details

Showing all: 8 variant(s).

Variant ID.	`1789`
Epitope Seq.	`ISPRTLNAW`
Variant Seq.	`raPRTLNAW`
Mutations	I/R S/A
Epitope Location	I1R S2A
HXB2 Location	I147R S148A
Mutation Type	NSF: non-susceptible form
Method	CD8 T-cell Elispot - IFNy, Tetramer binding
Note	None of the patients tested recognized the variant.

Variant ID.	`1790`
Epitope Seq.	`ISPRTLNAW`
Variant Seq.	`mSPRTLNAW`
Mutations	I/M
Epitope Location	I1M
HXB2 Location	I147M
Mutation Type	NSF: non-susceptible form SF: susceptible form
Method	CD8 T-cell Elispot - IFNy, Tetramer binding
Note	Some patients recognized the variant, some did not.

Variant ID.	`1791`
Epitope Seq.	`ISPRTLNAW`
Variant Seq.	`vSPRTLNAW`
Mutations	I/V
Epitope Location	I1V
HXB2 Location	I147V
Mutation Type	NSF: non-susceptible form SF: susceptible form
Method	CD8 T-cell Elispot - IFNy, Tetramer binding
Note	Some patients recognized the variant, some did not.

Variant ID.	`1792`
Epitope Seq.	`ISPRTLNAW`
Variant Seq.	`ltPRTLNAW`
Mutations	I/L S/T
Epitope Location	I1L S2T
HXB2 Location	I147L S148T
Mutation Type	NSF: non-susceptible form SF: susceptible form
Method	CD8 T-cell Elispot - IFNy, Tetramer binding
Note	Some patients recognized the variant, some did not.

Variant ID.	`1793`
Epitope Seq.	`ISPRTLNAW`
Variant Seq.	`vtPRTLNAW`
Mutations	I/V S/T
Epitope Location	I1V S2T
HXB2 Location	I147V S148T
Mutation Type	NSF: non-susceptible form SF: susceptible form
Method	CD8 T-cell Elispot - IFNy, Tetramer binding
Note	Some patients recognized the variant, some did not.

Variant ID.	`1794`
Epitope Seq.	`ISPRTLNAW`
Variant Seq.	`ISaRTLNAW`
Mutations	P/A
Epitope Location	P3A
HXB2 Location	P149A
Mutation Type	NSF: non-susceptible form SF: susceptible form
Method	CD8 T-cell Elispot - IFNy, Tetramer binding
Note	Some patients recognized the variant, some did not.

Variant ID.	`1795`
Epitope Seq.	`ISPRTLNAW`
Variant Seq.	`IaPRTLNAr`
Mutations	S/A W/R
Epitope Location	S2A W9R
HXB2 Location	S148A W155R
Mutation Type	NSF: non-susceptible form
Method	CD8 T-cell Elispot - IFNy, Tetramer binding
Note	None of the patients tested recognized the variant.

Variant ID.	`1796`
Epitope Seq.	`ISPRTLNAW`
Variant Seq.	`lSPRTLNAW`
Mutations	I/L
Epitope Location	I1L
HXB2 Location	I147L
Mutation Type	DR: diminished response SF: susceptible form
Method	CD8 T-cell Elispot - IFNy, Tetramer binding
Note	Some patients recognized the variant at the level of the index peptide, some had diminished response.

References

Turnbull2006 Emma L. Turnbull, A. Ross Lopes, Nicola A. Jones, David Cornforth, Phillipa Newton, Diana Aldam, Pierre Pellegrino, Jo Turner, Ian Williams, Craig M. Wilson, Paul A. Goepfert, Mala K. Maini, and Persephone Borrow. HIV-1 Epitope-Specific CD8+ T Cell Responses Strongly Associated with Delayed Disease Progression Cross-Recognize Epitope Variants Efficiently. J. Immunol., 176(10):6130-6146, 15 May 2006. PubMed ID: 16670322. Show all entries for this paper.

Displaying record number 55001

HXB2 Location Gag(162-172) Gag Epitope Map
View variants at this location

Epitope

KAFSPEVIPMF

Epitope Alignment

Variants

`rAFSPEVIPMF`		susceptible form
`KnFSPEVIPMF`		non-susceptible form; susceptible form
`KgFSPEVIPMF`		susceptible form
`KAFSPEiIPMF`		susceptible form
`KAFnPEVIPMF`		non-susceptible form; susceptible form
`KgFnPEVIPMF`		non-susceptible form; susceptible form
`KAFnPEiIPMF`		non-susceptible form; susceptible form
`KAFSPgVIPMF`		non-susceptible form

Epitope Name KAF

Species (MHC/HLA) human(B*57:01)

Variant Details

Showing all: 8 variant(s).

Variant ID.	`1797`
Epitope Seq.	`KAFSPEVIPMF`
Variant Seq.	`rAFSPEVIPMF`
Mutations	K/R
Epitope Location	K1R
HXB2 Location	K162R
Mutation Type	SF: susceptible form
Method	CD8 T-cell Elispot - IFNy, Tetramer binding
Note	This natural variant was recognized in all patients tested.

Variant ID.	`1798`
Epitope Seq.	`KAFSPEVIPMF`
Variant Seq.	`KnFSPEVIPMF`
Mutations	A/N
Epitope Location	A2N
HXB2 Location	A163N
Mutation Type	NSF: non-susceptible form SF: susceptible form
Method	CD8 T-cell Elispot - IFNy, Tetramer binding
Note	About half of patients tested recognized the variant, other patients had reduced or no response.

Variant ID.	`1799`
Epitope Seq.	`KAFSPEVIPMF`
Variant Seq.	`KgFSPEVIPMF`
Mutations	A/G
Epitope Location	A2G
HXB2 Location	A163G
Mutation Type	SF: susceptible form
Method	CD8 T-cell Elispot - IFNy, Tetramer binding
Note	All patients recognized the variant at >60% of the response to the index peptide.

Variant ID.	`1800`
Epitope Seq.	`KAFSPEVIPMF`
Variant Seq.	`KAFSPEiIPMF`
Mutations	V/I
Epitope Location	V7I
HXB2 Location	V168I
Mutation Type	SF: susceptible form
Method	CD8 T-cell Elispot - IFNy, Tetramer binding
Note	All patients recognized the variant at >60% of the response to the index peptide.

Variant ID.	`1801`
Epitope Seq.	`KAFSPEVIPMF`
Variant Seq.	`KAFnPEVIPMF`
Mutations	S/N
Epitope Location	S4N
HXB2 Location	S165N
Mutation Type	NSF: non-susceptible form SF: susceptible form
Method	CD8 T-cell Elispot - IFNy, Tetramer binding
Note	About half of patients tested recognized the variant, other patients had reduced or no response.

Variant ID.	`1802`
Epitope Seq.	`KAFSPEVIPMF`
Variant Seq.	`KgFnPEVIPMF`
Mutations	A/G S/N
Epitope Location	A2G S4N
HXB2 Location	A163G S165N
Mutation Type	NSF: non-susceptible form SF: susceptible form
Method	CD8 T-cell Elispot - IFNy, Tetramer binding
Note	2 patients had response about 80% of the response to the index peptide. Most patients had reduced or no response.

Variant ID.	`1803`
Epitope Seq.	`KAFSPEVIPMF`
Variant Seq.	`KAFnPEiIPMF`
Mutations	S/N V/I
Epitope Location	S4N V7I
HXB2 Location	S165N V168I
Mutation Type	NSF: non-susceptible form SF: susceptible form
Method	CD8 T-cell Elispot - IFNy, Tetramer binding
Note	1 patient had response comparable to the response to the index peptide. Most patients had reduced or no response.

Variant ID.	`1804`
Epitope Seq.	`KAFSPEVIPMF`
Variant Seq.	`KAFSPgVIPMF`
Mutations	E/G
Epitope Location	E6G
HXB2 Location	E167G
Mutation Type	NSF: non-susceptible form
Method	CD8 T-cell Elispot - IFNy, Tetramer binding
Note	None of the patients tested responded to this variant.

References

Displaying record number 55007

HXB2 Location Gag(259-267) Gag Epitope Map
View variants at this location

Epitope

GEIYKRWII

Epitope Alignment

Variants

`GdIYrRWII`		non-susceptible form
`rkIYKRWII`		non-susceptible form
`GdIYrkWIv`		non-susceptible form
`GnIYrRWIq`		non-susceptible form
`GEIYKRWIv`		diminished response; susceptible form
`GdIYKRWII`		diminished response; susceptible form
`GdIYKRWIv`		diminished response; non-susceptible form; susceptible form

Epitope Name GEI

Species (MHC/HLA) human(B*08:01)

Variant Details

Showing all: 7 variant(s).

Variant ID.	`1805`
Epitope Seq.	`GEIYKRWII`
Variant Seq.	`GdIYrRWII`
Mutations	E/D K/R
Epitope Location	E2D K5R
HXB2 Location	E260D K263R
Mutation Type	NSF: non-susceptible form
Method	CD8 T-cell Elispot - IFNy, Tetramer binding
Note	None of the patients tested responded to this variant.

Variant ID.	`1806`
Epitope Seq.	`GEIYKRWII`
Variant Seq.	`rkIYKRWII`
Mutations	G/R E/K
Epitope Location	G1R E2K
HXB2 Location	G259R E260K
Mutation Type	NSF: non-susceptible form
Method	CD8 T-cell Elispot - IFNy, Tetramer binding
Note	None of the patients tested responded to this variant.

Variant ID.	`1807`
Epitope Seq.	`GEIYKRWII`
Variant Seq.	`GdIYrkWIv`
Mutations	E/D K/R R/K I/V
Epitope Location	E2D K5R R6K I9V
HXB2 Location	E260D K263R R264K I267V
Mutation Type	NSF: non-susceptible form
Method	CD8 T-cell Elispot - IFNy, Tetramer binding
Note	None of the patients tested responded well to this variant.

Variant ID.	`1808`
Epitope Seq.	`GEIYKRWII`
Variant Seq.	`GnIYrRWIq`
Mutations	E/N K/R I/Q
Epitope Location	E2N K5R I9Q
HXB2 Location	E260N K263R I267Q
Mutation Type	NSF: non-susceptible form
Method	CD8 T-cell Elispot - IFNy, Tetramer binding
Note	None of the patients tested responded to this variant.

Variant ID.	`1809`
Epitope Seq.	`GEIYKRWII`
Variant Seq.	`GEIYKRWIv`
Mutations	I/V
Epitope Location	I9V
HXB2 Location	I267V
Mutation Type	DR: diminished response SF: susceptible form
Method	CD8 T-cell Elispot - IFNy, Tetramer binding
Note	Some patients had response at the level of the response to the index peptide. 2 patients had about 50% of the original response.

Variant ID.	`1810`
Epitope Seq.	`GEIYKRWII`
Variant Seq.	`GdIYKRWII`
Mutations	E/D
Epitope Location	E2D
HXB2 Location	E260D
Mutation Type	DR: diminished response SF: susceptible form
Method	CD8 T-cell Elispot - IFNy, Tetramer binding
Note	Some patients had response at the level of the response to the index peptide. 2 patients had about 50% of the original response.

Variant ID.	`1811`
Epitope Seq.	`GEIYKRWII`
Variant Seq.	`GdIYKRWIv`
Mutations	E/D I/V
Epitope Location	E2D I9V
HXB2 Location	E260D I267V
Mutation Type	DR: diminished response NSF: non-susceptible form SF: susceptible form
Method	CD8 T-cell Elispot - IFNy, Tetramer binding
Note	One patient responded at 80% of original response, 2 at 60%, 1 at 40% and 1 at 10%.

References

Displaying record number 55009

HXB2 Location Nef(73-82) Nef Epitope Map
View variants at this location

Epitope

QVPLRPMTYK

Epitope Alignment

Variants

`QVPLRPMTeK`		diminished response
`QVPvRPMTYK`		diminished response
`QVPiRPMTYK`		diminished response
`QVPLRPMTYq`		diminished response
`QVPLRPMTrr`		non-susceptible form
`QVPLRPMTYr`		non-susceptible form; susceptible form
`hVPLRPMTYK`		diminished response; susceptible form

Epitope Name QVP

Species (MHC/HLA) human(A*03:01)

Variant Details

Showing all: 7 variant(s).

Variant ID.	`1812`
Epitope Seq.	`QVPLRPMTYK`
Variant Seq.	`QVPLRPMTeK`
Mutations	Y/E
Epitope Location	Y9E
HXB2 Location	Y81E
Mutation Type	DR: diminished response
Method	CD8 T-cell Elispot - IFNy, Tetramer binding
Note	All patients tested had response <60% of the response to the index peptide.

Variant ID.	`1813`
Epitope Seq.	`QVPLRPMTYK`
Variant Seq.	`QVPvRPMTYK`
Mutations	L/V
Epitope Location	L4V
HXB2 Location	L76V
Mutation Type	DR: diminished response
Method	CD8 T-cell Elispot - IFNy, Tetramer binding
Note	All patients tested had response less or equal of 60% of the response to the index peptide.

Variant ID.	`1814`
Epitope Seq.	`QVPLRPMTYK`
Variant Seq.	`QVPiRPMTYK`
Mutations	L/I
Epitope Location	L4I
HXB2 Location	L76I
Mutation Type	DR: diminished response
Method	CD8 T-cell Elispot - IFNy, Tetramer binding
Note	All patients tested had response less or equal of 60% of the response to the index peptide.

Variant ID.	`1815`
Epitope Seq.	`QVPLRPMTYK`
Variant Seq.	`QVPLRPMTYq`
Mutations	K/Q
Epitope Location	K10Q
HXB2 Location	K82Q
Mutation Type	DR: diminished response
Method	CD8 T-cell Elispot - IFNy, Tetramer binding
Note	All patients tested had response less or equal of 60% of the response to the index peptide.

Variant ID.	`1816`
Epitope Seq.	`QVPLRPMTYK`
Variant Seq.	`QVPLRPMTrr`
Mutations	K/R Y/R
Epitope Location	K10R Y9R
HXB2 Location	K82R Y81R
Mutation Type	NSF: non-susceptible form
Method	CD8 T-cell Elispot - IFNy, Tetramer binding
Note	All patients tested had response less than 20% of the response to the index peptide.

Variant ID.	`1817`
Epitope Seq.	`QVPLRPMTYK`
Variant Seq.	`QVPLRPMTYr`
Mutations	K/R
Epitope Location	K10R
HXB2 Location	K82R
Mutation Type	NSF: non-susceptible form SF: susceptible form
Method	CD8 T-cell Elispot - IFNy, Tetramer binding
Note	Some patients tested had response comparable to the response to the index peptide, one patient had reduced response and two patients did not have a response.

Variant ID.	`1818`
Epitope Seq.	`QVPLRPMTYK`
Variant Seq.	`hVPLRPMTYK`
Mutations	Q/H
Epitope Location	Q1H
HXB2 Location	Q73H
Mutation Type	DR: diminished response SF: susceptible form
Method	CD8 T-cell Elispot - IFNy, Tetramer binding
Note	Some patients tested had response comparable to the response to the index peptide, one patient had reduced response (60%) and one patients had a response of 20% of the response to the index peptide.

References

Displaying record number 55006

HXB2 Location Nef(90-97) Nef Epitope Map
View variants at this location

Epitope

FLKEKGGL

Epitope Alignment

Variants

`FLKEqGGL`		non-susceptible form; susceptible form
`FLKEtGGL`		non-susceptible form; susceptible form
`FLKEnGGL`		diminished response; non-susceptible form
`FLKEmGGL`		diminished response; non-susceptible form; susceptible form
`FLKEeGGL`		diminished response; non-susceptible form
`FLrEKGGL`		diminished response; non-susceptible form
`FLKdKGGL`		non-susceptible form; susceptible form

Epitope Name FLK

Species (MHC/HLA) human(B*08:01)

Variant Details

Showing all: 7 variant(s).

Variant ID.	`1819`
Epitope Seq.	`FLKEKGGL`
Variant Seq.	`FLKEqGGL`
Mutations	K/Q
Epitope Location	K5Q
HXB2 Location	K94Q
Mutation Type	NSF: non-susceptible form SF: susceptible form
Method	CD8 T-cell Elispot - IFNy, Tetramer binding
Note	One patient had response comparable to the response to the index peptide, other had reduced or no response.

Variant ID.	`1820`
Epitope Seq.	`FLKEKGGL`
Variant Seq.	`FLKEtGGL`
Mutations	K/T
Epitope Location	K5T
HXB2 Location	K94T
Mutation Type	NSF: non-susceptible form SF: susceptible form
Method	CD8 T-cell Elispot - IFNy, Tetramer binding
Note	One patient had response comparable to the response to the index peptide, other had reduced or no response.

Variant ID.	`1821`
Epitope Seq.	`FLKEKGGL`
Variant Seq.	`FLKEnGGL`
Mutations	K/N
Epitope Location	K5N
HXB2 Location	K94N
Mutation Type	DR: diminished response NSF: non-susceptible form
Method	CD8 T-cell Elispot - IFNy, Tetramer binding
Note	All patients tested had either no response or response < 40% of response to the index peptide.

Variant ID.	`1822`
Epitope Seq.	`FLKEKGGL`
Variant Seq.	`FLKEmGGL`
Mutations	K/M
Epitope Location	K5M
HXB2 Location	K94M
Mutation Type	DR: diminished response NSF: non-susceptible form SF: susceptible form
Method	CD8 T-cell Elispot - IFNy, Tetramer binding
Note	All patients tested had either no response or response < 70% of response to the index peptide.

Variant ID.	`1823`
Epitope Seq.	`FLKEKGGL`
Variant Seq.	`FLKEeGGL`
Mutations	K/E
Epitope Location	K5E
HXB2 Location	K94E
Mutation Type	DR: diminished response NSF: non-susceptible form
Method	CD8 T-cell Elispot - IFNy, Tetramer binding
Note	All patients tested had either no response or response < 40% of response to the index peptide.

Variant ID.	`1824`
Epitope Seq.	`FLKEKGGL`
Variant Seq.	`FLrEKGGL`
Mutations	K/R
Epitope Location	K3R
HXB2 Location	K92R
Mutation Type	DR: diminished response NSF: non-susceptible form
Method	CD8 T-cell Elispot - IFNy, Tetramer binding
Note	All patients tested had either no response or response < 60% of response to the index peptide.

Variant ID.	`1825`
Epitope Seq.	`FLKEKGGL`
Variant Seq.	`FLKdKGGL`
Mutations	E/D
Epitope Location	E4D
HXB2 Location	E93D
Mutation Type	NSF: non-susceptible form SF: susceptible form
Method	CD8 T-cell Elispot - IFNy, Tetramer binding
Note	One patient responded at the level of the response to the index peptide, Other patients had < 40% of original response.